Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Achilles Therapeutics PLC

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
From Achilles Therapeutics PLC
Via GlobeNewswire
Tickers ACHL ARCT
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Tickers ACHL
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Tickers ACHL
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
From Achilles Therapeutics PLC
Via GlobeNewswire
Tickers ACHL
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
From Achilles Therapeutics PLC
Via GlobeNewswire
Tickers ACHL
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
From Achilles Therapeutics PLC
Via GlobeNewswire
Tickers ACHL
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Tickers ACHL
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Tickers ACHL
Achilles Therapeutics to Present at Upcoming Conferences
From Achilles Therapeutics PLC
Via GlobeNewswire
Tickers ACHL
Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Tickers ACHL
Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens
From Achilles Therapeutics PLC
Via GlobeNewswire
Tickers ACHL
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
From Achilles Therapeutics PLC
Via GlobeNewswire
Tickers ACHL
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status
From Achilles Therapeutics PLC
Via GlobeNewswire
Tickers ACHL
Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
From Achilles Therapeutics PLC
Via GlobeNewswire
Tickers ACHL
Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Tickers ACHL
Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Achilles Therapeutics PLC
Via GlobeNewswire
Tickers ACHL
Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022
From Achilles Therapeutics PLC
Via GlobeNewswire
Tickers ACHL
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
From Achilles Therapeutics PLC
Via GlobeNewswire
Tickers ACHL
Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method
From Achilles Therapeutics PLC
Via GlobeNewswire
Tickers ACHL
Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Tickers ACHL
Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy
From Achilles Therapeutics PLC
Via GlobeNewswire
Tickers ACHL
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.